ASCO 2021 VL

Single Priming Dose of 177Lu-PSMA-617 Followed by Pembrolizumab in mCRPC in a Phase 1b Trial - Rahul Aggarwal

Details
Alicia Morgans and Rahul Aggarwal, discuss the recent presentation on the phase 1b study of lutetium-177 combined with pembrolizumab. This phase I/II trial is evaluating the safety signals of the treatment combination. Biographies: Rahul Aggarwal, MD Assistant Professor of Hematology/Oncology, Director of STAND Clinic, UCSF Helen Diller Family Comprehensive Cancer Center Alicia Morgans, MD, MPH As...

Impact of Age on Castration Rates from The HERO Study – Michael Cookson

Details
Alicia Morgans, MD, MPH, and Michael Cookson, MD, MMHC, FACS, discuss age subgroups in the HERO trial, evaluating differences in castration rates between patients of different ages from the HERO Study. The HERO trial evaluated relugolix compared to standard androgen deprivation therapy with leuprolide. Dr. Cookson discusses how they performed the analysis. The evaluation demonstrated that younger...

Immunotherapy Treatments Across the Spectrum of Urothelial Cancer Stages - Bishoy Faltas

Details
Ashish Kamat, MD, MBBS, and Bishoy Faltas, MD, discuss immuno-oncology approaches across the spectrum of urothelial carcinoma. They discuss chemotherapy coupled with immune checkpoint inhibitors and how the combination may benefit patients with urothelial cancers. Further, they discuss the JAVELIN Bladder 100 trial, a randomized 700 patient trial that evaluated maintenance avelumab treatment. Biog...

42-Month Follow-up of KEYNOTE-426, Pembrolizumab plus Axitinib First-Line Treatment for Advanced Renal Cell Carcinoma - Thomas Powles

Details
Alicia Morgans, MD, MPH, and Thomas Powles, MBBS, MRCP, MD, discuss the recent ASCO presentation on 42 -month follow-up from the KEYNOTE-426 study. The KEYNOTE-426 study is a randomized phase three study looking at combination therapies of axitinib and pembrolizumab versus sunitinib, in metastatic kidney cancer. Biographies: Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead...

Practical Application of 18F-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer: The CONDOR Study - Michael Morris

Details
The CONDOR trial was one of two studies that supported the United States Federal Drug Administration (FDA) submission and subsequent approval of DCFPyL, an 18F radiolabeled PSMA directed PET tracer. The CONDOR trial focused specifically on the rising, the biochemically relapsed patient population, those who had surgery or radiation as their definitive primary therapy, biochemically relapsed, and t...

Health-Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma in the CLEAR Trial – Bradley McGregor

Details
The combination of lenvatinib and pembrolizumab in the CLEAR trial was found to significantly improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) as first-line therapy for patients with advanced renal cell carcinoma (RCC). CLEAR was a large randomized Phase 3 trial comparing lenvatinib in combination with pembrolizumab versus lenvatinib with everolimus...

Validating the Genomic Classifier to Identify Patients With a High Risk of Metastasis Among African American Men With Early Localized Prostate Cancer, VANDAAM Study – Kosj Yamoah

Details
When we think about prostate cancer health disparities, particularly there are two main areas of importance, understanding what the effects are and also figuring out what the implementation strategies could be. In this conversation with Alicia Morgans, Director of Radiation Oncology at the Moffitt Cancer Center, Kosj Yamoah highlights the currently enrolling VANDAAM Study, a prospective study vali...

Genomic Analysis and Assessment of Treatment Patterns To Better Understand Disparities in Advanced Prostate Cancer – Brandon Mahal

Details
In this UroToday discussion Charles Ryan and Brandon Mahal, discuss Dr Mahal’s recent update to his study that was published in last year’s New England Journal of Medicine. Dr. Mahal begins this conversation by discussing the background of his recent study, discussing the differences in mutational landscape, of advanced prostate cancer patients, between men with European and African ancestry. Dr....

Neoadjuvant Atezolizumab with Gemcitabine and Cisplatin in Patients with Muscle-Invasive Bladder Cancer - Samuel A. Funt

Details
In this UroToday discussion between Alicia Morgans and Samuel Funt, they discuss Samuel Funt’s recent phase 2 trial evaluating the use of atezolizumab, with gemcitabine and cisplatin, as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). The conversation begins with background on the study, beginning with Dr. Funt’s description of neoadjuvant cisplatin-based chemotherapy as the standar...

COncurrent adMinistration of Bipolar Androgen Therapy and nivolumab in men with mCRPC, The COMBAT Study - Mark Markowski

Details
In this UroToday discussion between Charles Ryan and Mark Markowski, they focus on Dr Markowski’s recent study, entitled COMAT-CRPC. The COMBAT-CRPC study is a study with bipolar androgen therapy and nivolumab, which was conducted through the Prostate Cancer Clinical Trials Consortium. Dr. Markowski begins by discussing the criteria for patient eligibility, which was quite broad, which was to be a...